ArticleMolecular biology reports2026
Caspase-1-mediated pyroptosis drives secondary thalamic neurodegeneration after focal cerebral infarction.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSecondary neurodegeneration in brain regions remote from the primary infarct contributes substantially to long-term neurological dysfunction after ischemic stroke. Although pyroptosis has been implicated in acute ischemic injury, its contribution to delayed secondary thalamic degeneration remains poorly understood. This study investigated whether canonical inflammasome-mediated pyroptosis contributes to secondary thalamic injury following focal cerebral infarction. METHODS AND
resultsA permanent distal middle cerebral artery electrocoagulation model was established in male C57BL/6 mice. Adeno-associated virus-mediated short hairpin RNA targeting caspase-1 was stereotactically delivered into the ipsilateral thalamus two weeks before ischemic injury. Behavioral assessments, histological analyses, immunofluorescence, and Western blotting were performed at predefined time points after infarction. Focal cortical ischemia induced marked activation of caspase-1 and downstream pyroptotic signaling within the ipsilateral thalamus, accompanied by progressive neuronal loss, astrocytic activation, and microglial polarization toward a pro-inflammatory phenotype. Targeted caspase-1 knockdown significantly improved sensory and cognitive performance, preserved thalamic neurons, reduced astrocyte proliferation, suppressed the expression of gasdermin D, interleukin-1β, and interleukin-18, and promoted polarization of Iba-1-positive cells toward an anti-inflammatory M2-like phenotype.
conclusionsCanonical inflammasome-mediated pyroptosis plays an important role in secondary thalamic neurodegeneration after focal cerebral infarction. Targeted inhibition of caspase-1 attenuated remote neuroinflammation and neurodegeneration, supporting canonical inflammasome signaling as a promising therapeutic target for limiting delayed brain injury following ischemic stroke.
Indexed as
Identifiers
42550293What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.